Corvus Pharmaceuticals, Inc. (CRVS) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	9.5	11.9	10.9	10.6	10.2	7.6	2.4
General and administrative	9.5	11.9	10.9	10.6	10.2	7.6	2.4
Research and development	29.1	31.8	38.0	38.6	46.3	29.4	11.4
Other operating expenses		-37.5
EBITDA [+]	-38.2	-5.7	-48.1	-48.4	-55.7	-36.4	-13.6
EBITDA growth	573.3%	-88.2%	-0.5%	-13.1%	53.0%	167.1%
Depreciation and amortization	0.5	0.6	0.7	0.8	0.8	0.6	0.1
EBIT [+]	-38.6	-6.3	-48.9	-49.2	-56.5	-37.0	-13.8
EBIT growth	513.1%	-87.1%	-0.7%	-12.9%	52.9%	168.5%
Non-recurring items [+]		37.5
Unusual expense		37.5
Other income (expense), net	-4.6	37.8	2.2	2.3	0.9	0.6	-17.6
Pre-tax income	-43.2	-6.0	-46.7	-46.9	-55.7	-36.4	-31.3
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-43.2	-6.0	-46.7	-46.9	-55.7	-36.4	-31.3

Basic EPS [+]	($1.03)	($0.20)	($1.59)	($1.71)	($2.72)	($2.36)	($83.86)
Growth	408.0%	-87.2%	-6.8%	-37.2%	15.2%	-97.2%
Diluted EPS [+]	($1.03)	($0.20)	($1.59)	($1.71)	($2.72)	($2.36)	($83.86)
Growth	408.0%	-87.2%	-6.8%	-37.2%	15.2%	-97.2%

Shares outstanding (basic) [+]	41.9	29.5	29.3	27.5	20.5	15.4	0.4
Growth	42.0%	0.4%	6.7%	34.3%	32.9%	4027.5%
Shares outstanding (diluted) [+]	41.9	29.5	29.3	27.5	20.5	15.4	0.4
Growth	42.0%	0.4%	6.7%	34.3%	32.9%	4027.5%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.